Literature DB >> 20884752

Enterobacteria modulate intestinal bile acid transport and homeostasis through apical sodium-dependent bile acid transporter (SLC10A2) expression.

Masaaki Miyata1, Hiroki Yamakawa, Mayumi Hamatsu, Hideaki Kuribayashi, Yuki Takamatsu, Yasushi Yamazoe.   

Abstract

In our study, ampicillin (AMP)-mediated decrease of enterobacteria caused increases in hepatic bile acid concentration through (at least in part) elevation of bile acid synthesis in C57BL/6N mice. We investigated the involvement of enterobacteria on intestinal bile acid absorption in AMP-treated mice in the present study. Fecal enterobacterial levels and fecal bile acid excretion rates were markedly decreased in mice treated with AMP (100 mg/kg) for 3 days, whereas bile acid concentrations in portal blood were significantly increased compared with those in mice treated with a vehicle. Ileal apical sodium-dependent bile acid transporter (SLC10A2) mRNA levels and ileal SLC10A2 protein levels in brush-border membranes were significantly increased compared with those in mice treated with the vehicle. In AMP-treated mice, total bile acid levels were increased, whereas levels of enterobacteria-biotransformed bile acid, taurodeoxycholic acid, and cholic acid were decreased in intestinal lumen. These phenomena were also observed in farnesoid X receptor-null mice treated with AMP for 3 days. Discontinuation of AMP administration after 3 days (vehicle administration for 4 days) increased levels of fecal enterobacteria, fecal bile acid excretion, and taurodeoxycholic acid and cholic acid in the intestinal lumen, whereas the discontinuation decreased ileal SLC10A2 expression and bile acid concentrations in the portal blood. Coadministration of taurodeoxycholic acid or cholic acid decreased ileal SLC10A2 expression in mice treated with AMP. These results suggest that enterobacteria-mediated bile acid biotransformation modulates intestinal bile acid transport and homeostasis through down-regulation of ileal SLC10A2 expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884752     DOI: 10.1124/jpet.110.171736

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

Review 1.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 2.  Intestinal Absorption of Bile Acids in Health and Disease.

Authors:  Alexander L Ticho; Pooja Malhotra; Pradeep K Dudeja; Ravinder K Gill; Waddah A Alrefai
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

Review 3.  Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.

Authors:  Jessica Tsuei; Thinh Chau; David Mills; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

Review 4.  Intestinal microbiome of poultry and its interaction with host and diet.

Authors:  Deng Pan; Zhongtang Yu
Journal:  Gut Microbes       Date:  2013-10-31

Review 5.  Cross-talk between bile acids and intestinal microbiota in host metabolism and health.

Authors:  Yang-fan Nie; Jun Hu; Xiang-hua Yan
Journal:  J Zhejiang Univ Sci B       Date:  2015-06       Impact factor: 3.066

Review 6.  The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review.

Authors:  N C Penney; J Kinross; R C Newton; S Purkayastha
Journal:  Int J Obes (Lond)       Date:  2015-06-17       Impact factor: 5.095

7.  Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption.

Authors:  Guoxiang Xie; Wei Zhong; Houkai Li; Qiong Li; Yunping Qiu; Xiaojiao Zheng; Huiyuan Chen; Xueqing Zhao; Shucha Zhang; Zhanxiang Zhou; Steven H Zeisel; Wei Jia
Journal:  FASEB J       Date:  2013-05-24       Impact factor: 5.191

Review 8.  The solute carrier family 10 (SLC10): beyond bile acid transport.

Authors:  Tatiana Claro da Silva; James E Polli; Peter W Swaan
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

Review 9.  Bile acid signaling in metabolic disease and drug therapy.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

10.  Regulation of intestinal cytochrome P450 expression by hepatic cytochrome P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure.

Authors:  Yi Zhu; Xinxin Ding; Cheng Fang; Qing-Yu Zhang
Journal:  Mol Pharmacol       Date:  2013-11-01       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.